JP4589728B2 - Ｃｃｒ５アンタゴニストとして有用なピペリジン誘導体 - Google Patents

Ｃｃｒ５アンタゴニストとして有用なピペリジン誘導体 Download PDF

Info

Publication number
JP4589728B2
JP4589728B2 JP2004562317A JP2004562317A JP4589728B2 JP 4589728 B2 JP4589728 B2 JP 4589728B2 JP 2004562317 A JP2004562317 A JP 2004562317A JP 2004562317 A JP2004562317 A JP 2004562317A JP 4589728 B2 JP4589728 B2 JP 4589728B2
Authority
JP
Japan
Prior art keywords
alkyl
aryl
compound
group
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004562317A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006515851A (ja
JP2006515851A5 (https=
Inventor
マイケル ダブリュー． ミラー，
ジャック ディー． スコット，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2006515851A publication Critical patent/JP2006515851A/ja
Publication of JP2006515851A5 publication Critical patent/JP2006515851A5/ja
Application granted granted Critical
Publication of JP4589728B2 publication Critical patent/JP4589728B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
JP2004562317A 2002-12-18 2003-12-17 Ｃｃｒ５アンタゴニストとして有用なピペリジン誘導体 Expired - Fee Related JP4589728B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43430602P 2002-12-18 2002-12-18
PCT/US2003/040619 WO2004056770A2 (en) 2002-12-18 2003-12-17 Piperidine derivatives useful as ccr5 antagonists

Publications (3)

Publication Number Publication Date
JP2006515851A JP2006515851A (ja) 2006-06-08
JP2006515851A5 JP2006515851A5 (https=) 2007-02-01
JP4589728B2 true JP4589728B2 (ja) 2010-12-01

Family

ID=32682021

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004562317A Expired - Fee Related JP4589728B2 (ja) 2002-12-18 2003-12-17 Ｃｃｒ５アンタゴニストとして有用なピペリジン誘導体

Country Status (16)

Country Link
US (2) US7307081B2 (https=)
EP (1) EP1581494A2 (https=)
JP (1) JP4589728B2 (https=)
KR (1) KR20050085700A (https=)
CN (2) CN100591678C (https=)
AR (1) AR042481A1 (https=)
AU (1) AU2003297400B2 (https=)
CA (1) CA2510027A1 (https=)
CL (1) CL2003002637A1 (https=)
MX (1) MXPA05006580A (https=)
MY (1) MY147899A (https=)
NZ (1) NZ540452A (https=)
PE (1) PE20040769A1 (https=)
TW (1) TWI331606B (https=)
WO (1) WO2004056770A2 (https=)
ZA (1) ZA200504772B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0509803A (pt) 2004-04-13 2007-09-18 Incyte Corp derivados de piperazinilpiperidina como antagonistas de receptor de quimiocina
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US7880002B2 (en) 2004-12-29 2011-02-01 Millennium Pharmaceuticals, Inc. Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
JP4769257B2 (ja) * 2005-02-23 2011-09-07 シェーリング コーポレイション ケモカインレセプターのインヒビターとして有用なピペリジニルピペラジン誘導体
EP1858886A1 (en) * 2005-02-23 2007-11-28 Schering Corporation Piperidinyl piperidine derivatives useful as inhibitors of chemokine receptors
US20070123538A1 (en) * 2005-11-30 2007-05-31 Schering Corporation Compositions comprising a combination of CCR5 and CXCR4 antagonists
US20080108586A1 (en) * 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
US20100063280A1 (en) * 2006-12-22 2010-03-11 Schering Corporation Process for preparing ccr-5 receptor antagonists utilizing 4-substituted 1-cyclopropane-sulfonyl-piperidinyl compounds
JP7611949B2 (ja) * 2023-01-27 2025-01-10 株式会社Ｓｃｒｅｅｎホールディングス 基板保持装置及びそれを備えた基板処理装置

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
DE19614204A1 (de) * 1996-04-10 1997-10-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US5952349A (en) 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
US5977138A (en) 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
CA2371583C (en) * 1999-05-04 2005-09-13 Schering Corporation Piperazine derivatives useful as ccr5 antagonists
HK1039330B (en) * 1999-05-04 2005-12-09 Schering Corporation Piperidine derivatives useful as ccr5 antagonists
PL364560A1 (en) * 2001-03-29 2004-12-13 Schering Corporation Ccr5 antagonists useful for treating aids
EP1373206B1 (en) * 2001-03-29 2008-12-24 Schering Corporation Aryl oxime-piperazines useful as ccr5 antagonists

Also Published As

Publication number Publication date
JP2006515851A (ja) 2006-06-08
AR042481A1 (es) 2005-06-22
KR20050085700A (ko) 2005-08-29
ZA200504772B (en) 2006-03-29
CN1729186A (zh) 2006-02-01
MXPA05006580A (es) 2005-08-16
CL2003002637A1 (es) 2005-04-08
CN101768152A (zh) 2010-07-07
TWI331606B (en) 2010-10-11
US20040132711A1 (en) 2004-07-08
WO2004056770A3 (en) 2004-08-12
NZ540452A (en) 2008-12-24
TW200427682A (en) 2004-12-16
WO2004056770A2 (en) 2004-07-08
AU2003297400B2 (en) 2010-03-11
AU2003297400A1 (en) 2004-07-14
CA2510027A1 (en) 2004-07-08
CN100591678C (zh) 2010-02-24
US20080095740A1 (en) 2008-04-24
MY147899A (en) 2013-01-31
PE20040769A1 (es) 2004-11-06
EP1581494A2 (en) 2005-10-05
US7307081B2 (en) 2007-12-11

Similar Documents

Publication Publication Date Title
JP4223950B2 (ja) Ｃｃｒ５アンタゴニストとして有用なピペリジン誘導体
CA2442227C (en) Ccr5 antagonists useful for treating aids
AU2002255947A1 (en) CCR5 antagonists useful for treating AIDS
US20080095740A1 (en) Piperidine derivatives useful as ccr5 antagonists
JP2008031180A (ja) ケモカインレセプターの阻害剤として有用なビピペリジニル誘導体
KR20080098541A (ko) Ｈｉｖ 치료에 유용한 ｃｃｒ5 길항제
JP4769257B2 (ja) ケモカインレセプターのインヒビターとして有用なピペリジニルピペラジン誘導体
JP4822367B2 (ja) ケモカイン受容体のインヒビターとして有用なピペリジニルピペリジン誘導体
MXPA06004963A (en) Bipiperidinyl derivatives useful as inhibitors of chemokine receptors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100308

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100607

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100722

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100811

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100910

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130917

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees